Adaptive Biotechnologies (ADPT) Change in Accured Expenses (2018 - 2026)

Adaptive Biotechnologies has disclosed Change in Accured Expenses across 9 years of filings, most recently posting -$7.5 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$7.5 million, up 22.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (up 155.77% YoY), and the FY2025 annual result was $665000.0, down 0.89% from the prior year.
• Change in Accured Expenses came in at -$7.5 million for Q1 2026 at Adaptive Biotechnologies, down from $1.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $10.5 million in Q4 2022 to a low of -$15.9 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $407000.0 (2024), against an average of -$263058.8.
• Across the five-year window, Change in Accured Expenses plunged 150.71% in 2023 and soared 10093.22% in 2025, its largest moves.
• Adaptive Biotechnologies' Change in Accured Expenses stood at $10.5 million in 2022, then tumbled by 49.3% to $5.3 million in 2023, then slipped by 20.13% to $4.3 million in 2024, then slumped by 72.68% to $1.2 million in 2025, then sank by 744.81% to -$7.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$7.5 million (Q1 2026), $1.2 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.